Terapie innovative

Le fratture della disuguaglianza in Oncologia pediatrica

Peccatori N, Biondi A.

2026/3 — pag. 167-169 — DOI

Paediatric oncology is one of the major success stories of modern medicine, yet it continues to reflect profound global and systemic inequities. While advances in biology, genetics and immunotherapy have dramatically improved outcomes for children wi...

Assistenza pediatrica 2020: quali prospettive? La formazione continua che vorremmo

2020/2 — pag. 82-84

Malattie rare a cavallo dell’innovazione: una sfida etica e scientifica

A. Tommasini, A. Magnolato, S. Pastore, I. Bruno

2018/10 — pag. 628-634

Recent advances in medicine are providing new opportunities to treat rare and complex disorders. Precision therapies are being developed to target molecular processes crucial to the disease pathogenesis. Media often present technological advances r...

Distrofia muscolare di Duchenne:stato dell’arte su nuovi approcci terapeutici

S. Messina, E. Mercuri

2016/9 — pag. 565-571

Duchenne muscular dystrophy is an X-linked disorder with an incidence of 1 in 5,000 male live births and is the most common muscular dystrophy in childhood. The disease is characterized by progression of muscle weakness and contractures leading to ...

Nuovi concetti nel campo della distrofia muscolare di Duchenne

M. Pane, F. Bianco, C. Palermo, A. Graziano, E. Mercuri

2012/7 — pag. 429-435

Duchenne muscular dystrophy has an incidence of 1 in 3,500 male live births and is the most common muscular dystrophy in childhood. The “typical” course of the disease is characterized by progression of muscle weakness and contractures leading to l...